Drug Profile
Research programme: anti-cancer monoclonal antibodies - Savoy Pharmaceuticals
Alternative Names: OncoprevLatest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Savoy Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 22 Sep 2023 Anti-cancer monoclonal antibodies is still in preclinical development for Cancer in USA (Savoy Pharmaceuticals pipeline, September 2023)
- 30 Jan 2019 Research programme: anti-cancer monoclonal antibodies is still in Preclinical trials for cancer in USA (Savoy Pharmaceuticals pipeline, January 2019)
- 28 Apr 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)